Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Head and Neck Neoplasms 2Triple Negative Breast Neoplasms 1Tongue Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Serotonin Syndrome 1Salivary Gland Malignancy 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Inflammatory Breast Neoplasms 1Colorectal Neoplasms 1Colorectal Adenocarcinoma Metastatic to the Liver 1Carcinoid Tumor 1Adenoma, Pleomorphic 1

Interventions

gallium Ga 68 dotatate 2veliparib 1telotristat ethyl 1Temozolomide 1Panitumumab 1Octreotide 1Capecitabine 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Carcinoid Tumor × Panitumumab × Clear all
NCT01172717 2013-07-26

Study of Panitumumab in the Treatment of Carcinoid Syndrome

Boston Medical Center

Phase 2 Withdrawn
Endocrine

Carcinoid Tumor, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡